Skip to content
PIL Logo

Ancotil 2.5g/250ml Solution for Infusion

Last Updated on eMC 04-May-2017 View changes  | Meda Pharmaceuticals Contact details

The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine. It is written for patients and gives information about taking or using a medicine. It is possible that the leaflet in your medicine pack may differ from this version because it may have been updated since your medicine was packaged.

Please click on the link to the left to view the PIL in PDF format.

Text only version for the visually impaired
Below is a text only representation of the Patient Information leaflet. The original may contain images or tables and can be viewed in PDF format using the link to the left. This PIL may be available from the RNIB in large print, Braille or audio CD. For further information please call the RNIB Medicine Leaflet line on 0800 198 5000. The product code(s) for this leaflet is/are: PL 15142/0002.

Ancotil 2.5g/250ml Solution for Infusion

Patient Information Leaflet

Ancotil® 2.5 g/250ml

(1g in 100 ml)

Solution for Infusion


Read all of this leaflet carefully before you start using this medicine.

  • Keep this leaflet. You may need to read it again.
  • This leaflet tells you about Ancotil.
  • It does not contain all the information about Ancotil.
  • If you have any questions or are unsure of anything ask the doctor or nurse.
  • If you experience any side effect and this becomes serious, tell your doctor or pharmacist.

In this leaflet:

1. What Ancotil is and what it is used for
2. Before you are given Ancotil
3. How Ancotil is given
4. Possible side effects
5. How Ancotil is stored
6. Further information


Ancotil Solution for Infusion contains an anti-fungal agent. It is used to treat certain yeast and fungal infections.


You should not be given Ancotil

  • If you are allergic (hypersensitive) to flucytosine or any of the other ingredients of Ancotil (these are listed in section 6, “Further Information”).
  • If you are breast-feeding.
  • If you are using any medicine known as an antiviral nucleoside (e.g. ganciclovir, valganciclovir, brivudine, sorivudine). These medicines are usually used to treat chickenpox and shingles.

Take special care with Ancotil

Tell your doctor before you start treatment

  • If you have a liver, kidney or blood problem. Your doctor may need to carry out blood tests during your treatment.

Using other medicines

Females of childbearing potential under treatment must use effective contraceptive during treatment and for one month after treatment. Male patients (or their female partners of childbearing potential) must use effective contraception during treatment and for three months after treatment (See Pregnancy and breastfeeding section).

Tell your doctor before you start treatment if you are taking or have recently taken any other medicines, including medicines obtained without a prescription. In particular, tell your doctor if you are taking the medicine cytarabine (which is used to treat certain leukaemias), medicines to treat chickenpox or shingles (brivudine, sorivudine) or have used them in the last 4 weeks.

These medicines may increase the possibility of unwanted effects with Ancotil. If you are taking medicines for epilepsy containing phenytoin, your doctor may do some blood tests.

Pregnancy and breast-feeding

You must tell your doctor before you start treatment if you are pregnant, if you think you may get pregnant or if you are breast-feeding.

  • Your doctor will decide whether you should be given Ancotil if you are pregnant. If Ancotil is administered in pregnancy, there is a risk of causing malformations (abnormally formed parts of the body) to the unborn baby and careful before and after birth monitoring should be performed.
  • You should not be given Ancotil if you are breast-feeding.

Contraception in males and females

Females of childbearing potential under treatment must use effective contraceptive during treatment and for one month after treatment. Male patients (or their female partners of childbearing potential) must use effective contraception during treatment and for three months after treatment.


Ancotil is administered only in a hospital and is administered by a doctor or nurse. It is usually given into a vein or by a procedure called “intraperitoneal infusion” while you are in hospital.

The usual total daily dose is 100 to 150 mg/kg bodyweight in divided doses.

In some instances, you may be given up to a total daily dose of 200 mg/kg bodyweight in divided doses.

Smaller doses may be given to patients with kidney problems.

The treatment period with Ancotil will vary on a patient by patient basis, but treatment will not usually be longer than a week.

Ancotil can be given with a glucose and/or saline infusion. It should not be mixed in the same solution with other medicines.


Like all medicines, Ancotil can cause side effects, although not everybody gets them.

Your doctor will monitor your reaction to Ancotil. Possible side effects include:

  • Nausea, vomiting, diarrhoea and skin rashes may occur but these usually do not last long.

Less frequent side effects include:

  • Allergic reaction. If you have an allergic reaction you may experience palpitations, swelling of eyelids, face, lips, mouth or tongue, sudden wheeziness, chest tightness, lumpy skin rash.
  • Skin inflammation that may lead to severe blistering.
  • Effects on the heart muscle and its pumping.
  • Confusion, effects on your senses (e.g. seeing or hearing things), fits, headache, sleepiness and dizziness.
  • Tests on your blood may show changes to your liver or certain factors in your blood.
  • Ancotil contains 34.5 mmol (or 0.8 g) sodium/250 ml solution for infusion. To be be taken into consideration by patients on a controlled sodium diet.

If you are concerned about any of these side effects, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects, you can help provide more information on the safety of this medicine.

For the United Kingdom:

Yellow Card Scheme

For the Republic of Ireland:

HPRA Pharmacovigilance
Earlsfort Terrace
IRL - Dublin 2
Tel: +353 1 6764971
Fax: +353 1 6762517


  • All medicines should be kept out of the reach and sight of children.
  • Hospital staff should store Ancotil between 18 °C and 25 °C.
  • This product should not be used after the expiry date shown on the bottle label after “EXP”. The expiry date refers to the last day of that month.
  • Before administration, Ancotil should be visually inspected for any particulate matter and discolouration.
  • Do not use Ancotil if you notice that there are any visible particles, precipitation or discolouration.
  • For single use only. Discard any remaining contents after use.
  • The product should only be handled by experienced healthcare professionals.
  • Medicines should not be disposed of via wastewater or household waste. The pharmacist should provide instructions as to how to dispose of medicines no longer required. These measures will help to protect the environment.


What Ancotil Solution for Infusion contains

Active substance: Flucytosine. Each infusion bottle contains 2.5 g in 250 ml (1 g in 100 ml) of flucytosine

Other ingredients: Sodium chloride, tromethamine, hydrochloric acid, and water for injections.

What Ancotil Solution for Infusion looks like and contents of the pack

  • Ancotil Solution for Infusion is a clear, colourless to slightly yellow solution.
  • Ancotil Solution for Infusion is available in packs of 5 bottles of 250 ml.

Marketing Authorisation Holder

Meda Pharmaceuticals Ltd.
Skyway House
Parsonage Road
Bishops Stortford
CM22 6PU

Meda Health Sales Ireland Limited
Unit 34/35
Block A
Dunboyne Business Park
Co. MeathIreland


Meda Pharma GmbH & Co. KG
Benzstrasse 1
61352 Bad Homburg

For any information about this medicine, please contact the Marketing Authorisation Holder.

This leaflet was last revised in April 2017.


Company contact details

Meda Pharmaceuticals

Company image

Sky Way House, Parsonage Road, Takeley, Bishop's Stortford, CM22 6PU


0845 460 0002

Medical Information e-mail
Out of Hours contact

+44 (0)1748 828 810


0845 460 0000

Medical Information Direct Line

+44 (0)1748 828 810

Medical Information Fax

+44 (0)1748 828 801

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Active ingredients


Legal categories

POM - Prescription Only Medicine

This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue